23andMe said it is still working with the FDA for approval of those tests, as well as analyzes that can predict a person's response to specific drugs.
Tests for inherited genetic risks of breast cancer, and drug response, are already available in other countries such as the United Kingdom, Canada and Sweden.
"There's more work ahead on the other areas but I'm optimistic," 23andMe co-founder and Chief Executive Anne Wojcicki said in an interview.
The new test service, available beginning on Wednesday, will allow healthy people to see if they carry a genetic variant related to 36 conditions that could be passed on to a child, the company said. The conditions, apart from cystic fibrosis, include sickle cell anemia, Tay-Sachs disease and beta thalassemia.
The service also provides non-medical details on traits like freckles or hair curliness as well as a person's lactose intolerance.
Priced at $199, the service comes about eight months after U.S. regulators approved 23andMe's carrier screening test for Bloom's Syndrome, a disorder that causes short stature and a predisposition to cancer.
The FDA said at the time that the company could offer carrier screening tests to customers without seeking regulatory approval first. 23andMe said it has spent the intervening time, prior to Wednesday's launch, validating the new tests to make sure they meet FDA standards.
Carrier tests are generally only done on healthy people considering having families and are not used to assess an individual's personal risk for disease.
Healthy individuals who are carriers have inherited one normal and one abnormal variant of a gene associated with a disorder. A child must inherit two aberrant copies — one from each parent — to develop symptoms.